Myelodysplastic neoplasms (MDS), historically known as myelodysplastic syndromes, persist as a formidable challenge in hematology due to their heterogeneous nature and complex pathophysiology. These disorders encompass a spectrum of clonal myeloid malignancies primarily characterized by ineffective hematopoiesis, leading to peripheral blood cytopenias and an increased, albeit variable, risk of progression to acute myeloid leukemia (AML). Despite concerted research efforts spanning over two decades, therapeutic interventions specifically targeting the underlying biology of MDS remain limited, with allogeneic hematopoietic stem cell transplantation (HSCT) standing as the sole curative approach to date. This review delves into the recent advances elucidating the genetic underpinnings, diagnostic refinements, risk stratification paradigms, and emergent treatment strategies, while also addressing critical obstacles hampering therapeutic progress.
The epidemiology of MDS highlights its predilection for the elderly, with a median age of diagnosis around 76 years in the United States, underscoring the need for age-adjusted management approaches. The increasing global aging population portends a rising incidence and burden of MDS, necessitating improved diagnostic accuracy and therapeutic innovation. Epidemiological data further underscore challenges in surveillance and reporting, owing to evolving classification systems that influence disease categorization and clinical trial enrollment criteria. Moreover, the heterogeneity of clinical phenotypes and genetic aberrations complicate the derivation of robust epidemiological trends, emphasizing the need for standardized global registries.
At the heart of MDS pathogenesis lie intricate, multifactorial genetic alterations. Advances in next-generation sequencing technologies have unveiled a complex genomic landscape involving recurrent somatic mutations affecting epigenetic regulation, splicing machinery, signal transduction pathways, and transcription factors. Notably, mutations in genes such as SF3B1, TET2, DNMT3A, ASXL1, and TP53 have been recurrently implicated. This mutational heterogeneity not only influences disease phenotype and prognosis but also shapes responses to existing therapies and potential targets for novel agents. Concurrently, germline predisposition syndromes, once considered rare, are increasingly recognized contributors to MDS pathobiology, mandating comprehensive genetic testing approaches.
Immunological dysfunction constitutes a critical facet of MDS pathophysiology. The bone marrow milieu in MDS exhibits chronic inflammation, immune dysregulation, and impaired immune surveillance, which collectively promote clonal evolution and disease progression. Aberrant activation of innate immune pathways, including toll-like receptor signaling and inflammasome activity, perpetuates a pro-inflammatory microenvironment. Additionally, the role of adaptive immunity, particularly T-cell exhaustion and altered regulatory T-cell dynamics, is gaining recognition for its contribution to ineffective hematopoiesis and therapeutic resistance. These immunological insights open avenues for immunomodulatory treatments aiming to restore marrow homeostasis.
Diagnostic approaches to MDS have undergone significant refinement, integrating morphological assessment with sophisticated molecular and cytogenetic techniques. Conventional bone marrow morphology and cytogenetics remain foundational; however, the incorporation of molecular profiling has revolutionized diagnostic precision. This integration enables differentiation of MDS from other myeloid neoplasms and bone marrow failure states, facilitating personalized prognostication and therapeutic selection. The 2022 update to the World Health Organization (WHO) and International Consensus Classification (ICC) systems reflects these advancements, though such changes pose challenges for longitudinal data comparison and trial design.
Risk stratification models play a pivotal role in MDS management by guiding therapeutic decision-making and prognostication. The Revised International Prognostic Scoring System (IPSS-R) remains widely utilized, incorporating clinical, cytogenetic, and hematologic parameters. Nonetheless, emerging models integrating molecular mutation data, such as the Molecular International Prognostic Scoring System (IPSS-M), offer superior predictive accuracy. These models facilitate the identification of high-risk patients who may benefit from early intervention and low-risk individuals who might be managed with supportive care. The integration of dynamic biomarkers also holds promise for real-time risk assessment.
Therapeutically, the landscape of MDS is evolving but continues to lag behind other hematologic malignancies. Hypomethylating agents (HMAs) such as azacitidine and decitabine constitute the backbone of treatment for higher-risk MDS, yet their efficacy is limited, with many patients relapsing or exhibiting resistance. Efforts to combine HMAs with novel agents targeting specific molecular abnormalities or the immune microenvironment are underway. Novel therapeutics include inhibitors of BCL-2, spliceosome modulators, and agents targeting inflammatory signaling pathways. Additionally, advances in precision medicine and molecularly guided trials promise to reshape the therapeutic paradigm.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative modality for MDS. However, the procedure’s applicability is limited by patient age, comorbidities, donor availability, and transplant-associated risks. Recent improvements in conditioning regimens, donor selection, and post-transplant care have enhanced outcomes, yet long-term survivorship and relapse prevention remain significant hurdles. Identifying patients who might derive maximal benefit from transplantation, potentially guided by molecular risk stratification, is an active area of investigation. Moreover, novel approaches like adoptive immunotherapy and maintenance post-transplant regimens aim to reduce relapse.
The evolving classification systems, while reflective of deeper biological insights, present unique challenges in clinical trial design and epidemiological reporting. Shifts in diagnostic criteria necessitate harmonization of historical data with contemporary cohorts to ensure valid comparisons and meta-analyses. Trial enrollment challenged by phenotypic heterogeneity requires adaptive designs and biomarker-driven inclusion criteria to optimize therapeutic evaluations. Furthermore, standardization in reporting adverse events and treatment outcomes is critical to facilitate regulatory approval processes and guideline development.
Research into the bone marrow microenvironment highlights its integral role in MDS development and progression. The interplay between clonal hematopoietic cells and their stromal, immune, and endothelial counterparts influences disease dynamics. Niche alterations, including fibrosis, abnormal cytokine profiles, and disrupted cellular interactions, contribute to ineffective hematopoiesis and clonal dominance. Understanding these complex cellular and molecular interactions opens new therapeutic avenues targeting the microenvironment to restore normal hematopoiesis and inhibit malignant progression.
Technological advancements are a driving force behind current and future MDS research. High-throughput single-cell sequencing, sophisticated computational modeling, and spatial transcriptomics are unraveling the intra-tumoral heterogeneity and the bone marrow ecosystem’s complexity. These tools facilitate the identification of novel biomarkers, therapeutic targets, and mechanisms of treatment resistance. Integrative multi-omics approaches, combining genomics, epigenomics, transcriptomics, and proteomics, are poised to enable precise disease phenotyping and personalized medicine.
Despite these advances, significant unmet needs persist in the field. The lack of reliable biomarkers for early diagnosis, disease monitoring, and prediction of therapeutic response remains a barrier to optimized care. Resistance to frontline therapies, including HMAs, is common and poorly understood mechanistically, limiting durable responses. Additionally, the challenge of managing MDS in elderly patients with comorbidities necessitates tailored, less toxic therapeutic approaches. Coordinated international efforts and multidisciplinary collaboration are essential to overcome these barriers.
Future research directions emphasize the development of therapies aimed at the molecular and immunological derangements unique to individual patients. Clinical trials focusing on combination regimens, targeting multiple pathogenic mechanisms concurrently, hold promise. Efforts to integrate real-world data and patient-reported outcomes into clinical decision-making frameworks will enhance personalized care delivery. Moreover, the potential for early intervention in clonal hematopoiesis prior to overt MDS manifestation represents a paradigm shift toward disease prevention.
In conclusion, the evolving understanding of myelodysplastic neoplasms integrates complex genomic aberrations, immune dysregulation, and microenvironmental factors that collectively drive disease pathogenesis. While allogeneic HSCT remains the cornerstone of curative therapy, the expanding therapeutic armamentarium, bolstered by molecular insights and innovative trial designs, heralds a future of precision medicine in MDS. Addressing current challenges through collaborative research and technological innovation is imperative to improve outcomes for this predominantly elderly patient population burdened by one of hematology’s most enigmatic disorders.
Subject of Research: Myelodysplastic neoplasms (myelodysplastic syndromes), focusing on epidemiology, pathophysiology, diagnosis, classification, risk stratification, and therapeutic advances.
Article Title: A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.
Article References:
Bewersdorf, J.P., Mina, A., Stahl, M. et al. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01141-2
Image Credits: AI Generated
